Floatz logo

MICAFUNGIN

Systemic Fungal Infections

Astellas Pharma Europe B.V.Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Systemic Fungal Infections cohort.

Asset / SponsorPhaseRating
Fluconazole
Radboud University Medical Center
Phase 4BB
Isavuconazole
Astellas Pharma Inc
Phase 3BB
Oxygen
Jay C. Buckey Jr.
Phase 4BB
Fosmanogepix
Basilea Pharmaceutica
Phase 2CCC

Same molecule, other indications

MICAFUNGIN is also rated in:

nutritional deficiency diseaseDormant
B
Indicative ·
61 / 100
View asset →
morbid obesityDormant
B
Indicative ·
60 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →